BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results ...

Fintel reports that on March 21, 2025, Cantor Fitzgerald initiated coverage of GlycoMimetics (NasdaqCM:GLYC) with a ...

Exicure (XCUR) announced that the Australian Patent Office has issued Patent No. 2018388302, titled “GPCR Heteromer Inhibitors and Uses ...

Exicure, Inc. (Nasdaq: XCUR) today announced that the Australian Patent Office has issued Patent No. 2018388302, titled "GPCR Heteromer Inhibitors and Uses Thereof." This patent covers the company’s ...

The canonical chemokine receptor CXCR4 and atypical receptor ACKR3 both respond to CXCL12 but induce different effector responses to regulate cell migration. While CXCR4 couples to G proteins and ...

The chemokine receptor CXCR4 and its ligand CXCL12 play an important homeostatic function by mediating the homing of progenitor cells in the bone marrow and regulating their mobilization into ...

Following up on this discovery, the researchers investigated whether CXCL12 is involved in the recruitment of CD8+ cells by blocking the corresponding receptor (CXCR4) for this signaling protein ...

CD8 + T cells accumulate in atherosclerotic plaques. LMU researchers identify a crucial signaling pathway—with therapeutic potential. For a long time, macrophages and foam cells were considered ...

It has been recently demonstrated that chemokine receptor-4 (CXCR4) is overexpressed in sporadic VS as well as in NF2 tumors and that hearing disability and CXCR4 expression may be correlated. Further ...